Reference entry

Tesamorelin

Also listed as Egrifta WR

Read the scope, examine the source, and keep your own question alongside the evidence.

Status labels apply within the product, route, and use described below. Read the limitations alongside that scope.

Scoped product status: Approved product
Evidence label: Randomized evidence

Status as of 2026-10-27

Reference fields

Sources for these fields

Product and use: Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
Route context: Specified subcutaneous formulation.
Mechanism: Stimulates growth-hormone release.
Evidence: A randomized trial measured visceral fat.
Limitations: Not for weight management.
Safety: Active malignancy is a contraindication.

From a report to your question

Where a measurement is missing, keep the blank separate from any story about what happened. Check whether the report explains whose information is unavailable, when the gap arose, and how the analysis treats it. If a conclusion depends on an assumption about those unobserved values, look for an examination of alternative assumptions. Your note can distinguish an unanswered measurement question from the explanation proposed to bridge it. That leaves room to assess the reasoning without treating an absent observation as either a favorable or an unfavorable result.

Questions to consider

Whose measurements are unavailable, and when did the information gap arise?
What assumptions connect the missing information with the conclusion presented?
Would another plausible assumption change how the result answers my question?

Sources

These references support the fields as a group. Follow a source to check the original wording and its scope.

EGRIFTA WRNLM · Checked 2026-10-27
Falutz trialPubMed · Checked 2026-10-27

Continue reading

Reading topics: Hormones. These organize the library and do not describe recommended uses.

Educational reference information. No clinician review is claimed. This entry does not provide personal medical advice.